Axiom Research, LLC | Colton, CA

Research site

(Unclaimed)

Location

900 E Washington Street, Suite 210, Colton, California, United States of America

Site insights

Top conditions

Top treatments

Cariprazine

Troriluzole

ABP-450

Simufilam

Rimegepant

Atogepant

Erenumab

MK-1942

BI 425809

Zavegepant

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

7 of 24 total trials

Efficacy and Safety Study of Adjunctive Troriluzole in Obsessive Compulsive Disorder

The study's purpose is to evaluate the efficacy and safety of troriluzole as adjunctive therapy compared to placebo in subjects with Obsessive Compul...

Enrolling

Obsessive-Compulsive Disorder

Drug: Placebo

Drug: Troriluzole

Efficacy and Safety Study of Rimegepant in Episodic Migraine Prevention With Multiple Dosing Regimens

The purpose of this study is to compare the efficacy and safety of daily and every other day dosing of rimegepant to placebo as a preventive treatmen...

Active, not recruiting

Migraine

Drug: Placebo comparator dosing

Drug: Rimegepant 75mg every other day dosing

Long-term Safety Study of Adjunctive Troriluzole in Subjects With Obsessive Compulsive Disorder

The purpose of the study is to evaluate the long term safety and tolerability of troriluzole as adjunctive therapy in subjects with obsessive compuls...

Invitation-only

Obsessive Compulsive Disorder

Drug: Troriluzole (BHV-4157)

Locations recently updated

Open-label Extension for Phase 3 Clinical Trials of Simufilam

The goal of this open-label extension study is to assess long-term safety and tolerability of simufilam 100 mg in subjects who have completed the RET...

Invitation-only

Alzheimer Disease

Drug: Simufilam

Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms

The purpose of this study is to know how well seltorexant works, and also to evaluate safety and maintenance effect of seltorexant compared with plac...

Enrolling

Depressive Disorder, Major

Drug: Selective Serotonin Reuptake Inhibitor (SSRI)/Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)

Drug: Placebo

Simufilam 100 Mg for Mild-to-Moderate Alzheimer's Disease (RETHINK-ALZ)

A 52-week safety and efficacy study of simufilam (PTI-125) given twice daily to participants with mild-to-moderate Alzheimer's disease (AD) for 52 we...

Active, not recruiting

Alzheimer Disease

Drug: Placebo

Drug: Simufilam

Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine

A migraine is a moderate to severe headache typically on one side of the head. A migraine attack is a headache that may be accompanied by throbbing,...

Enrolling

Migraine

Drug: Ubrogepant

Drug: Placebo for Ubrogepant